Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.45 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23867194 | 1.00 | MAP4K4 (0.55) | MAP4K4HDAC1GPR119GRM1SUV39H2 | |
| SCHEMBL30124551 | 1.00 | MAP4K4 (0.55) | MAP4K4HDAC1GPR119GRM1SUV39H2 | |
| SCHEMBL23867113 | 1.00 | MAP4K4 (0.55) | MAP4K4HDAC1GPR119GRM1SUV39H2 | |
| SCHEMBL38665473 | 0.87 | PARP1 (0.44) | MAP4K4HDAC1GPR119NR1H2NR1H3 | |
| SCHEMBL38663998 | 0.87 | PARP1 (0.44) | MAP4K4HDAC1GPR119NR1H2NR1H3 | |
| SCHEMBL23867109 | 0.87 | MAP4K4 (0.55) | MAP4K4HDAC1GPR119GRM1SUV39H2 | |
| SCHEMBL38666767 | 0.86 | DPP4 (0.43) | MAP4K4HDAC1GPR119NR1H2NR1H3 | |
| SCHEMBL38665057 | 0.86 | DPP4 (0.43) | MAP4K4HDAC1GPR119NR1H2NR1H3 | |
| SCHEMBL4573445 | 0.86 | MAP4K4 (0.54) | MAP4K4HDAC1GPR119GRM1SUV39H2 | |
| SCHEMBL31658417 | 0.85 | MAP4K4 (0.52) | MAP4K4HDAC1GPR119GRM1SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697990-B | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12053469-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-115697990-A | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4121422-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | MAP4K4 2175/4885HDAC1 1476/4885GPR119 2318/4885 |
| US-12053469-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | MAP4K4 2175/4885HDAC1 1476/4885GPR119 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.